Business Wire

Ricardo: UK Consortium to Deliver World’s First Truly Green Passenger Carrying Airline Services Using Hydrogen Fuel Cell Technology

30.3.2021 02:01:00 EEST | Business Wire | Press release

Share

Cranfield Aerospace Solutions (CAeS) - the UK SME leading the Project Fresson consortium - announces it will exploit recent advances in hydrogen fuel cell technology to develop a commercially viable, retrofit powertrain solution for the nine-passenger Britten-Norman Islander aircraft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005667/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Project Frisson to deliver world's first green passenger aircraft service (Graphic: Business Wire)

Following a rigorous assessment of hydrogen technology innovators, CAeS is delighted to welcome Ricardo UK Ltd and Innovatus Technologies Ltd to the Fresson consortium. Ricardo UK Ltd brings expertise in fuel cell system development and Innovatus Technologies Ltd brings their innovative Scottish Hydrogen Fuel Tank (SHyFT) technology.

Steve Dyke, Managing Director Ricardo Automotive and Industrial EMEA Division said: “We are proud to join the Cranfield Aerospace Solutions consortium to play our part in helping to reduce the carbon footprint for commercial air passengers. We are already working on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. Our work for the Fresson consortium will enable us to consolidate and grow our hydrogen fuel cell and propulsion capability, so that Ricardo can achieve its ambition of becoming a world-leader in hydrogen and fuel cell services and solutions and help accelerate net zero transportation.”

Innovatus Technologies Ltd leads the field in next generation ultralightweight hydrogen tank design exploiting patented cellular core composite techniques. This is critical to the successful integration and exploitation of hydrogen fuel cell power systems in applications across aerospace, automotive, industrial, and marine sectors.

Ruan Swart, Chief Executive Officer Innovatus Technologies Ltd said: ““We are proud in being selected to join the Cranfield Aerospace Solutions, ‘Project Fresson’, consortium. Our unique and innovative SHyFT solution is game-changing in bringing zero carbon fuel cell energy to commercial reality in the transport sector. Project Fresson showcases important Scottish innovation and next generation hydrogen tank manufacturing in the UK.”

Project Fresson will deliver an emissions-free (zero CO2), hydrogen-fuel-cell-powered flying demonstrator by September 2022. Having completed a comprehensive evaluation of technologies and configurations for sustainable aircraft propulsion, the Fresson team concluded that hydrogen fuel cell technology is the optimum solution to meet environmental, regulatory and operational requirements for this size of aircraft, enabling zero carbon emissions and reducing operating costs. This has presented the Fresson consortium, which includes Britten-Norman and Cranfield University, with an opportunity to deliver an enhanced technology programme that surpasses the original demonstrator concept.

Paul Hutton, Chief Executive Officer, Cranfield Aerospace Solutions said: “This is incredibly important for the Project Fresson Team but also for everyone else around the world interested in zero emissions flight. This project can deliver the world’s first truly “green” passenger carrying airline services. The whole team is proud of what Project Fresson has achieved so far and excited about what is to come. I am very thankful for the support of the ATI and our investors for making this ground-breaking work a reality.”

Jenny Kavanagh, Chief Strategy Officer, Cranfield Aerospace Solutions added: “Covid-19 has caused the biggest crisis in aviation’s history. It’s important that, as the sector builds back better, it does so with sustainability at its heart. Project Fresson is more than just a technology demonstrator; it has one focus above all others: real operational and commercial viability.”

Project Fresson is supported by the ATI Programme, a joint Government and industry investment to maintain and grow the UK’s competitive position in civil aerospace design and manufacture. The programme, delivered through a partnership between the Aerospace Technology Institute (ATI), Department for Business, Energy & Industrial Strategy (BEIS) and Innovate UK, addresses technology, capability and supply chain challenges.

As a result of these changes, there is now no longer a need for the Rolls-Royce element of the aircraft programme. It is therefore Rolls-Royce’s intention to withdraw from Project Fresson and the consortium is going through the necessary steps for this to happen. We thank Rolls-Royce for its contribution to Project Fresson and wish its team well. Rolls-Royce will continue to actively research the use of hydrogen in aviation and this decision in no way reflects its overall view of hydrogen as a potential technology.

Ends

Notes to editors

  • To follow the progress of Project Fresson, visit the microsite: www.projectfresson.uk or follow on Twitter @projectfresson.
  • Cranfield Aerospace Solutions (CAeS) is an aerospace market leader in rapid prototyping of new aerospace concepts, modifications to existing aerospace platforms and integration of cutting-edge technologies to meet the most challenging issues facing the industry today. CAeS is the wholly owned commercial arm of Cranfield University. Visit: www.cranfieldaerospace.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contacts
For Cranfield Aerospace Solutions:
Telephone: +44 (0) 1234 754046
Email: enquiries@cranfieldaerospace.com

For Ricardo
Kathryn Bellamy
Communications Manager
Ricardo Automotive & Industrial EMEA Division, and Performance Products Division
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye